GlobalData on MSN6d
UK-based Verdiva launches with $410m and an oral GLP-1RA candidate
Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...
GlobalData on MSN21h
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m
Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
GlobalData on MSN2d
Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025
CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in ...
Medscape2d
Drug-Drug Interactions With Glucagon-like Peptide-1 Receptor Agonists
Objective: To review drug interaction studies of glucagon-like ... needed to further assess and allow comparison of several GLP-1RA agents' impact on steady-state pharmacokinetics and ...
STAT36m
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
Medscape2h
GLP-1s Show No Increased Risk for Thyroid Cancer
In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...
Why GLP-1 Drugs Are Real Threat To McDonald's Golden Arches
McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.
TCTMD5d
Variety of GLP-1 Drugs Help People Without Diabetes Lose Weight: Review
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
FoodNavigator6d
GLP-1 – diet food killer or new opportunity?
Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...